Ruxolitinib in Patients With Myelofibrosis
NCT05762874 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 51
Last updated 2023-03-10
Summary
Prospective study to evaluate the response of myelofibrosis patients to ruxolitinib and it's adverse events on patients (1 year observational study).
Conditions
Interventions
- DRUG
-
JAK inhibitor
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-31
- Primary Completion
- 2025-03-31
- Completion
- 2025-06-30
- FDA Drug
- Yes
More Related Trials
-
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
NCT04097821 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
NCT05714072 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
NCT02718300 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis
NCT06909136 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
NCT06773195 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.
NCT02598297 ·Status: TERMINATED ·Phase: PHASE3
-
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
NCT01375140 ·Status: COMPLETED ·Phase: PHASE2
-
Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy
NCT03959371 ·Status: UNKNOWN
-
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
NCT04551053 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
NCT07340138 ·Status: RECRUITING ·Phase: PHASE1
-
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
NCT01433445 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
NCT01317875 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
NCT02436135 ·Status: TERMINATED ·Phase: PHASE1
-
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
NCT01969838 ·Status: COMPLETED ·Phase: PHASE3
-
JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis
NCT01795677 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
NCT02076191 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
INCB018424 in Patients With Advanced Hematologic Malignancies
NCT00674479 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis
NCT02370706 ·Status: COMPLETED ·Phase: PHASE1
-
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
NCT03558607 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04551066 ·Status: TERMINATED ·Phase: PHASE3
-
Study of SB939 in Subjects With Myelofibrosis
NCT01200498 ·Status: COMPLETED ·Phase: PHASE2
-
Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
NCT01392443 ·Status: COMPLETED ·Phase: PHASE2
-
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
NCT04281498 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Tolerability Study of Jaktinib
NCT05279001 ·Status: RECRUITING ·Phase: PHASE1
-
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
NCT05280509 ·Status: RECRUITING ·Phase: PHASE1/PHASE2